AlphAIAlphAI — Financial news for AI agents
tradingview.com$ECOR

ECOR Q3'26 Earnings: revenue estimate is 10.93M USD

ECOR (electroCore, Inc.) will report Q3'26 earnings on October 29. Analysts estimate revenue of $10.93M and EPS of -$0.27. The announcement is expected at 8:00 AM ET.

Original reporting
tradingview.com
Published Oct 22, 2026, 11:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 11:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
ECOR Q3'26 Earnings: revenue estimate is 10.93M USD — source image
Source · tradingview.com
Decision brief

The 30-second read

$ECORNeutralLow
01

Why it matters

The article only shares analyst estimates; no actual results are disclosed.

02

Market read

A low‑impact earnings preview for a micro‑cap; unlikely to move broader markets.

03

What to watch

Potential hidden contracts or regulatory approvals not mentioned in the preview.

Relevance 4/10Novelty 2/10Timing: pre‑market on Oct 29

Background

ElectroCore, Inc. (ECOR) is a medical‑device company awaiting its Q3'26 earnings release.

Company-level read

Ticker impact

$ECORNeutralLow confidence
Context

Article provides Q3'26 revenue and EPS estimates ahead of the earnings release on Oct 29.

Expected impact

potential slight pressure if results miss estimates, modest upside if beat

Evidence & confidence

Micro‑cap earnings preview with small dollar amounts; no material new catalyst.

Market effects

Sector

Limited impact on the medical device sector; earnings preview only.

Regional

No broader regional effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

If the company surprises to the upside, the stock could rally sharply despite low expectations.

Key entities

  • Company
    ElectroCore, Inc.

    Medical‑device maker reporting Q3'26 earnings.

Read at source← All news

Related articles

$ECORMed

electroCore, Inc. (ECOR): Third quarter 2026 net sales of $9.7 million, an increase of 12% over $8.7 million in the third quarter of 2025

electroCore, Inc. (ECOR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 electroCore Announces Third Quarter 2026 Financial Results Third quarter 2026 net sales of $9.7 million, an increase of 12% over $8.7 million in the third quarter of 2025 Net loss of $1.3 million decreased 61% from prior year with Adjusted EBITDA net loss improving 6

SEC EDGAR 8-K
$ECORMed

electroCore submits FDA 510(k) application for CIPN device

electroCore (NASDAQ:ECOR) submitted a 510(k) application to the FDA for its Quell device to treat chemotherapy-induced peripheral neuropathy (CIPN). The submission is based on two studies showing pain score reductions and improvements in neuropathy symptoms. FDA clearance is not guaranteed, and Quell is not currently approved for CIPN.

investing.com
$ECORMed

electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)

electroCore, Inc. (ECOR) submitted a 510(k) premarket notification to the FDA seeking clearance for its Quell® device to treat chronic chemotherapy-induced peripheral neuropathy (CIPN). The submission is supported by clinical studies showing symptom improvements. If cleared, Quell would be among the first FDA-cleared devices for CIPN. The FDA review process is underway, with no guarantee of clearance.

globenewswire.com
$ECORMed

electroCore, Inc. (ECOR): Second quarter 2026 net sales of $9.5 million, an increase of 28% over $7.4 million in the second quarter 2025

electroCore, Inc. (ECOR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 electroCore Announces Second Quarter 2026 Financial Results Second quarter 2026 net sales of $9.5 million, an increase of 28% over $7.4 million in the second quarter 2025 Net loss of $3.1 million decreased 17% from prior year with Adjusted EBITDA net loss improving 2

SEC EDGAR 8-K